The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937–970. doi:10.1002/cac2.12359
   PubMed Web of Science ®Google Scholar
• Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–1684. doi:10.1200/JCO.2017.77.0412
   PubMed Web of Science ®Google Scholar
• Mosca M, Conci N, Di Federico A, et al. First-generation epidermal growth factor receptor inhibitors plus antiangiogenic drugs versus third-generation epidermal growth factor receptor inhibitors in advanced non-small-cell lung cancer: a meta-analysis. JCO Precis Oncol. 2023;7:e2300073. doi:10.1200/PO.23.00073
   PubMed Web of Science ®Google Scholar
• Chen Z, Jiang S, Li X, et al. Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials. Ann Palliat Med. 2021;10(3):2687–2698. doi:10.21037/apm-20-1621
   PubMed Web of Science ®Google Scholar
• Xie C, Zhou X, Liang C, et al. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer. J Exp Clin Cancer Res. 2021;40(1):266. doi:10.1186/s13046-021-02069-4
   PubMed Web of Science ®Google Scholar
• Xiang Z, Deng X, He W, et al. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Ann Med. 2022;54(1):1357–1371. doi:10.1080/07853890.2022.2071977
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang G, Li W, et al. Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: a retrospective real-world study. Thorac Cancer. 2023;14(33):3275–3281. doi:10.1111/1759-7714.15118
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen Q, Zhang Y, et al. Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study. Cancer Chemother Pharmacol. 2023;92(5):411–418. doi:10.1007/s00280-023-04563-2
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Otsubo K, Kishimoto J, Ando M, et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. Eur Respir J. 2022;60(6):2200380. doi:10.1183/13993003.00380-2022
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155. doi:10.1016/S1470-2045(13)70586-2
   PubMed Web of Science ®Google Scholar
• Cheng Y, Han B, Li K, et al. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: subgroup analysis in the ALTER0303 trial. Cancer Med. 2020;9(8):2621–2630. doi:10.1002/cam4.2913
   PubMed Web of Science ®Google Scholar
• Zhang L, Fang WF, Yu Q, et al. A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER). J Clin Oncol. 2021;39(Suppl 15):S9131. doi:10.1200/JCO.2021.39.15_suppl.TPS9131
   Google Scholar
• Zhang L, Shi MQ, Huang C, et al. A Phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J Clin Oncol. 2012;30(Suppl 15):7548. doi:10.1200/jco.2012.30.15_suppl.7548
   Web of Science ®Google Scholar
• Zhang Z, Zhang Y, Luo F, et al. Dual blockade of EGFR and VEGFR pathways: results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. Clin Transl Med. 2020;10(2):e33. doi:10.1002/ctm2.33
   PubMed Web of Science ®Google Scholar
• Zhao H, Yao W, Min X, et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the Phase III ACTIVE Study (CTONG1706). J Thorac Oncol. 2021;16(9):1533–1546. doi:10.1016/j.jtho.2021.05.006
   PubMed Web of Science ®Google Scholar
• Song ZZ, Zhao LF, Zuo J, Fan ZS, Wang L, Wang YD. Clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer in patients who progressed after standard therapy and analysis of the KDR gene polymorphism. Onco Targets Ther. 2020;13:603–613. doi:10.2147/OTT.S222985
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Wen L, et al. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, Phase IV study. BMC Med. 2023;21(1):173. doi:10.1186/s12916-023-02841-7
   PubMed Web of Science ®Google Scholar
• Wang F, Jin F, Cheng B, Zhang Y, Zhou Q, Wang S. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2022;148(7):1721–1735. doi:10.1007/s00432-021-03752-x
   PubMed Web of Science ®Google Scholar